MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, AVLN had $39,995K increase in cash & cash equivalents over the period. -$30,209K in free cash flow.

Cash Flow Overview

Change in Cash
$39,995K
Free Cash flow
-$30,209K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Maturities of marketable securit...
    • Proceeds from sale of marketable...
    • Proceeds from term loan
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Accrued liabilities
    • Accounts payable
    • Others

Cash Flow
2026-03-31
Net loss
-26,869
Depreciation
63
Non-cash operating lease expense
109
Stock-based compensation expense
1,193
Amortization and accretion of premiums/discounts on marketable securities
237
Amortization of debt discount and deferred financing costs
5
Prepaid expenses and other current assets
508
Other assets
0
Accounts payable
-1,113
Accrued liabilities
-2,464
Operating lease liability
-70
Net cash used in operating activities
-29,891
Purchases of property and equipment
318
Purchases of marketable securities
0
Proceeds from sale of marketable securities
26,342
Maturities of marketable securities
29,000
Net cash provided by investing activities
55,024
Proceeds from the exercise of stock options
25
Proceeds from term loan
15,000
Payments of issuance costs associated with term loan
163
Net cash provided by financing activities
14,862
Increase (decrease) in cash and cash equivalents
39,995
Beginning of period
52,315
End of period
92,310
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Maturities of marketablesecurities$29,000K Proceeds from sale ofmarketable securities$26,342K Proceeds from term loan$15,000K Proceeds from theexercise of stock options$25K Net cash provided byinvesting activities$55,024K Net cash provided byfinancing activities$14,862K Canceled cashflow$318K Canceled cashflow$163K Increase (decrease) incash and cash...$39,995K Canceled cashflow$29,891K Purchases of property andequipment$318K Stock-based compensationexpense$1,193K Non-cash operating leaseexpense$109K Depreciation$63K Amortization of debt discountand deferred...$5K Payments of issuancecosts associated with...$163K Net cash used inoperating activities-$29,891K Canceled cashflow$1,370K Net loss-$26,869K Accrued liabilities-$2,464K Accounts payable-$1,113K Prepaid expenses andother current assets$508K Amortization and accretion ofpremiums/discounts on marketable...$237K Operating lease liability-$70K

Avalyn Pharma Inc. (AVLN)

Avalyn Pharma Inc. (AVLN)